Year-end Sale % OFF 
Abstract
Lung cancer is the leading cause of cancer deaths worldwide. Antiangiogenic agents have been established as one of the various treatment options for this type of tumor. However, it has not been possible to establish a biomarker that allows the selection of patients who will most benefit from this treatment. Recent publications suggest that the response to antiangiogenic agents is influenced by the presence of KRAS, TP53 or STK11/LKB1 gene mutations. The aim of this study was to establish the relationship between the presence of tumor mutations and the response to antiangiogenic agents.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
